



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE

Date: 19.05.2026

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of Marketing Authorization for Dabigatran Etexilate (75 mg, 110 mg & 150 mg) Capsules in Italy, Europe

Please find enclosed herewith the Press Release relating to grant of Marketing Authorization for Dabigatran Etexilate (75 mg, 110 mg & 150 mg) Capsules in Italy, Europe to the Wholly owned European Subsidiary of the Company

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: as above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

PRESS RELEASE

ZIM Laboratories Limited Announces Grant of Marketing Authorization (MA) for Dabigatran Etexilate (75 mg, 110 mg & 150 mg) Capsules in Italy, Europe

Nagpur, India May 19, 2026:

About ZIM Laboratories Limited

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The Company is pleased to announce today that Agenzia Italiana del Farmaco (AIFA) – the Italian Medicines Agency – has granted Marketing Authorization (MA) for ZIM’s anticoagulant product “Dabigatran Etexilate” (75 mg, 110 mg & 150 mg hard capsules)”, in Italy via DCP to its wholly owned European subsidiary, SIA ZIM Laboratories Limited, Latvia.

This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities.

Dabigatran Etexilate Capsules are indicated for the prevention and treatment of thromboembolic disorders, including stroke prevention in patients with non-valvular atrial fibrillation. The product has been developed using ZIM Laboratories Limited’s proprietary non-tartaric acid-based formulation design incorporating a novel excipient system and has demonstrated bioequivalence with the innovator product.

According to IQVIA, the EU market size for this product in 2025 was approximately USD 392.84 MN while Italy contributed 60.91 MN USD.